[Medical strategy in patients awaiting emergency heart transplantation].
Cardiac transplantation is theoretically the optimal final treatment of terminal cardiac failure but the indications, especially in the emergency situation, should be carefully considered. Sympathomimetic agents are of limited use in patients with severe cardiac failure partly because of the down regulation of the myocardial beta-receptors. The phosphodiesterase inhibitors, represented by enoximone, are valuable because of their action on the cardiac muscle (inotropic and lusitropic) and their direct systemic vasodilator effect. Enoximone can be administered by intravenous bolus resulting in a rapid onset of action (peak at 30 minutes) with a prolonged effect due to its hepatic metabolites. The authors' experience in this indication dates over 5 years and over 50 patients were included. A preliminary study in 34 patients with cardiac failure resistant to betamimetic drugs, referred to the intensive care unit for urgent cardiac transplantation, or, in the absence of a donor, circulatory assistance is reported. A Swan Ganz catheter and radial artery canula were inserted for haemodynamic monitoring and enoximone was administered in an intravenous bolus over 15 minutes every 8 hours in addition to sympathomimetic agents. A haemodynamic improvement was observed after the 30th minute in 30 patients. The cardiac index increased from 1.82 to 2.67 l/mn/m2 and the pulmonary capillary pressures decreased from 30.8 to 18.9 mmHg. Systemic arterial resistances fell from 2,170 to 1,520 dynes.s.cm-5. No haemodynamic improvement was observed in 4 patients who were treated by mechanical ventricular assistance. After investigations to detect contra-indications to cardiac transplantation, 12 of the 30 patients remained candidates for cardiac transplantation.(ABSTRACT TRUNCATED AT 250 WORDS)
Dubois-Randé
J L
JL
CHU Henri-Mondor, Créteil.
Loisance
D
D
Benvenuti
C
C
Deleuze
P
P
Saal
J P
JP
Lellouche
D
D
Duval-Moulin
A M
AM
Merlet
P
P
Castaigne
A
A
Cachera
J P
JP
D000328:Adult; D001243:Assisted Circulation; D002303:Cardiac Output, Low / Q000503:physiopathology / Q000628:therapy; D002316:Cardiotonic Agents / Q000008:administration & dosage; D000075202:Contraindications; D003422:Critical Care / Q000379:methods*; D004232:Diuretics / Q000008:administration & dosage; D004280:Dobutamine / Q000008:administration & dosage; D004298:Dopamine / Q000008:administration & dosage; D004630:Emergencies; D017335:Enoximone; D005260:Female; D006333:Heart Failure / Q000503:physiopathology / Q000628:therapy; D016027:Heart Transplantation; D006439:Hemodynamics; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012770:Shock, Cardiogenic / Q000503:physiopathology / Q000628:therapy
D002316:Cardiotonic Agents; D004232:Diuretics; D007093:Imidazoles; D004280:Dobutamine; D017335:Enoximone; D004298:Dopamine
Stratégie médicale chez les patients en attente de greffe cardiaque en urgence.